IA
GMAB icon

IFP Advisors’s Genmab GMAB Stock Holding History

IFP Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17K Sell
79
-23
-23% -$611 ﹤0.01% 4202
2026
Q1 		$2.74K Buy
102
+2
+2% +$60 ﹤0.01% 3834
2025
Q4 		$3.08K Hold
100
– – ﹤0.01% 3665
2025
Q3 		$3.07K Hold
100
– – ﹤0.01% 3506
2025
Q2 		$2.07K Sell
100
-20
-17% -$411 ﹤0.01% 3885
2025
Q1 		$2.35K Buy
120
+7
+6% +$147 ﹤0.01% 3091
2024
Q4 		$2.36K Buy
113
+40
+55% +$879 ﹤0.01% 3045
2024
Q3 		$1.78K Buy
73
+10
+16% +$267 ﹤0.01% 2940
2024
Q2 		$1.58K Hold
63
– – ﹤0.01% 2873
2024
Q1 		$1.88K Buy
63
+20
+47% +$588 ﹤0.01% 2715
2023
Q4 		$1.37K Hold
43
– – ﹤0.01% 2762
2023
Q3 		$1.52K Buy
43
+31
+258% +$1.18K ﹤0.01% 2906
2023
Q2 		$456 Buy
+12
New +$478 ﹤0.01% 3209
2023
Q1 		– Sell
-499
Closed -$26K – 3801
2022
Q4 		$26K Sell
499
-39
-7% -$1.61K ﹤0.01% 2688
2022
Q3 		$28K Buy
538
+39
+8% +$1.37K ﹤0.01% 2813
2022
Q2 		$26K Hold
499
– – ﹤0.01% 2635
2022
Q1 		$26K Buy
+499
New +$17.1K ﹤0.01% 2635

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFP Advisors's GMAB Position: Q2 2026 in Review

IFP Advisors reduced its Genmab (GMAB) stake by 23% in Q2 2026, selling an estimated $611 and leaving 79 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #4202.

IFP Advisors first reported a position in GMAB in Q1 2022 and has held it in 17 quarters since. The position peaked at $28K in Q3 2022. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • IFP Advisors held 79 shares of Genmab worth $2.17K as of Q2 2026.
  • IFP Advisors sold 23 Genmab shares in Q2 2026, an estimated $611.
  • Genmab made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4202 holding.
  • IFP Advisors first reported a position in Genmab in Q1 2022 and has held it in 17 quarters since.
  • IFP Advisors's Genmab position peaked at $28K in Q3 2022.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.